人重组沙眼衣原体疫苗的研究进展  

Progress in research on recombinant Chlamydia trachomatis vaccine

作　　者：尹晨亮 张庶民(综述) 徐颖华[3] 倪现朴(审校)[1] YIN Chen-liang;ZHANG Shu-min;XU Ying-hua;NI Xian-pu(Shenyang Pharmaceutical University,Shenyang 110000,Liaoning Province,China;不详)

机构地区：[1]沈阳药科大学生命科学与生物制药学院,辽宁沈阳110000 [2]北京成大天和生物科技有限公司,北京102600 [3]中国食品药品检定研究院卫生部生物技术产品检定方法及其标准化重点实验室,北京102629

出　　处：《中国生物制品学杂志》2022年第7期874-878,共5页Chinese Journal of Biologicals

基　　金：国家重点研发计划项目(2018YFC1603900)。

摘　　要：沙眼衣原体(Chlamydia trachomatis,CT)是一种革兰阴性、专性细胞内寄生的原核细胞型微生物,是引起性传播感染(sexually transmitted infection,STI)的重要病原体,可导致眼部、生殖道等多个系统疾病。疫苗是预防和控制CT感染最有效、最经济的方法,可实现对易感人群的长期保护,减少传播并抑制继发性感染。随着生物学技术的发展和抗CT感染免疫保护机制研究的深入,已发现一些具有潜在免疫保护性候选抗原蛋白,其中重组CT疫苗CTH522已进入Ⅰ期临床试验,并取得突破性进展。本文就近年对CT特异性免疫反应、重组疫苗候选抗原临床前研究和临床试验的研究进展及面临的挑战作一综述,以期为我国新CT疫苗的研发提供参考。Chlamydia trachomatis(CT)is an important Gram negative pathogen which is a prokaryotic microorganism specifically parasitic in cells and causes sexually transmitted infection(STI)resulting in diseases in various systems such as eyes and genital tract.Vaccine is the most effective and economic measure to prevent and control CT infection,which provides a long-term protection to susceptible population,decreases the transmission and inhibits the secondary infection.With the development of biological technology and the in-depth research on the immune protection mechanism against CT infection,some candidate antigen proteins with potential immune protection have been discovered,among which recombinant CT vaccine CTH522 has entered phase I clinical trial and has made a breakthrough.This article reviews the progress and challenges in research on CT specific immune response as well as preclinical research and clinical trials of recombinant vaccine candidate antigens in recent years so as to provide a reference for the development of new CT vaccine in China.

关 键 词：沙眼衣原体 重组疫苗 候选抗原 佐剂 动物模型 

分 类 号：R392-33[医药卫生—免疫学]